Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Health Care M&A Deals, February 5, 2021
The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our HealthCareMandA.com Deal Database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week by disclosed price is Jazz Pharmaceuticals plc’s acquisition of GW Pharmaceuticals plc for for $7.2 billion. GW Pharmaceuticals is a global pharmaceutical company that discovers, develops, manufactures and commercializes novel, regulatory approved therapeutics from its proprietary cannabinoid product platform to address a broad range of... Read More »
Jazz Pharmaceuticals Buys GW Pharmaceuticals
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is back with a new acquisition. The Ireland-based pharmaceutical company has announced the purchase of GW Pharmaceuticals plc (OTC: GWPRF) for $7.2 billion, or $220 per American Depositary Share in the form of $200 in cash and $20 in Jazz Pharmaceuticals ordinary shares. The price represents a premium of approximately 50% over GW’s closing stock price on February 2, 2021, of $146.25 and 60% over GW’s 30-day volume-weighted average price of $137.17. GW Pharmaceuticals is a global pharmaceutical company that discovers, develops, manufactures and commercializes novel, regulatory approved therapeutics from its proprietary cannabinoid product... Read More »
WELL Health Acquires CRH Medical Corporation
WELL Health Technologies Corp. (TSX.V: WELL) had an incredibly busy year in 2020, announcing eight deals, according to search results in our Healthcare Deals Database. Most of its activity focused on smaller eHealth targets to build up its digital health platform, but now WELL Health is turning its attention to the physician market. On Monday, the company announced the acquisition of CRH Medical Corporation (NYSE: CRHM), which provides physicians with innovative services and products for the treatment of gastrointestinal diseases. CRH serves 69 ambulatory surgical centers in 13 states. The purchase price came out to be $292.7 million, or $4.00 per share for CRH, a premium of approximately... Read More »
Veracyte Snaps Up Decipher Biosciences, Inc.
Veracyte, Inc. (NASDAQ: VCYT), the South San Francisco, California-based diagnostics company, has bought Decipher Biosciences, Inc for $600 million consisting of $250 million in cash and up to $350 million in stock. Decipher Biosciences is a commercial-stage precision oncology company focused on urologic cancers. It has a comprehensive portfolio of tests which leverage whole transcriptome analysis and proprietary machine learning algorithms to improve patient decision-making across the clinical care continuum. This acquisition solidifies Veracyte’s global position in the genomic cancer diagnostics market while accelerating revenue growth. Collectively, Decipher’s genomic tests have... Read More »
Healthcare Services Bankruptcies Spiked in 2020
Even before the Covid-19 pandemic arrived in the United States early in 2020, observers expected the flow of healthcare services bankruptcies filings by small rural hospitals and other service organizations stressed by regulatory and reimbursement challenges to continue at a steady trickle. Once the economic and social shutdowns began in mid-March, hospitals were forced to suspend elective procedures, emergency room visits plummeted, physician practices largely closed temporarily and home health agencies experienced a wave of visit cancellations. The cost of personal protective equipment, a requirement for healthcare workers, soared to astronomical highs. Of course, merger and acquisition... Read More »
MB2 Dental Solutions Finds a New Partner
After Sentinel Capital Partners took a majority interest in MB2 Dental Solutions (MB2), the dental services organization became a prolific buyer in the healthcare M&A market, building a national network of practices. The organization has a presence in 24 states and has partnered with more than 275 dental practices. In 2019, MB2 had an estimated revenue of $320 million. Now that partnership has ended. Sentinel Capital Partners is exiting its investment and Charlesbank Capital Partners will become the new majority owner. Charlesbank Capital Partners is a middle-market private investment firm managing more than $7 billion of capital. Charlesbank focuses on management-led buyouts and... Read More »
MultiPlan Corporation Acquires Discovery Health Partners
MultiPlan Corporation (NYSE: MPLN), a leading value-add provider of data analytics and technology-enabled end-to-end cost management solutions to the U.S. healthcare industry, is wasting no time in expanding. If the name rings a bell, it’s because MultiPlan just went public in July 2020 in an $11 billion reverse merger with Churchill Capital Corp III, a special purpose acquisition company (SPAC). It was one of the biggest deals of 2020, and one of many in healthcare involving a reverse merger with a SPAC. Since MultiPlan went public, the company has announced two transactions under its “Enhance-Extend-Expand strategy,” including the most recent one for Discovery Health Partners, valued at... Read More »
Horizon Therapeutics Acquires Viela Bio
Horizon Therapeutics plc (NASDAQ: HZNP) has been a major player in the healthcare M&A market for the last few years. According to search results in our Healthcare Deal Database, the company last reported a deal in April 2020, acquiring Curzion Pharmaceuticals, Inc., a San Diego-based biotechnology firm developing treatments for rare fibrotic diseases, for a modest $45 million. However, Horizon Therapeutics is back with a new deal, buying Viela Bio, Inc. in a $3.05 billion deal. Viela Bio is a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases. The company has a substantial pipeline... Read More »
Hill-Rom Holdings Hits the Ground Running
Only a month into the new year and Hill-Rom Holdings, Inc. (NYSE: HRC) already has two acquisitions on the books, according to search results in our Healthcare Deal Database. Hill-Rom Holdings operates as a medical technology company worldwide. Its products enable earlier diagnosis and treatment, optimize surgical efficiency and accelerate patient recovery while simplifying clinical communication and shifting care closer to home. Back on January 19, the medical device company acquired Bardy Diagnostics, Inc. for $375 million in cash, plus net operating losses valued at more than $20 million. Bardy Diagnostics was founded in 2013 and helps improve clinical management and outcomes for... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
